ARS Pharmaceuticals, Inc. SPRY Financing Liability
Financing Liability at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept spry:FinancingLiability.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s financing liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s financing liability?
- ARS Pharmaceuticals, Inc. (SPRY) reported financing liability of $74.67M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s financing liability changed year-over-year?
- ARS Pharmaceuticals, Inc.'s financing liability increased by 7.6% year-over-year, from $69.38M to $74.67M.
- What does financing liability mean?
- This represents non-standard financial obligations or debt-like instruments that do not fall under traditional accounts payable or long-term debt categories. It captures unique financing arrangements, such as deferred payment obligations or specialized credit facilities, that impact the company's overall leverage profile. Investors track this to understand the total burden of non-operating financial commitments on the company's capital structure.